https://www.selleckchem.com/products/go-6983.html
g is not readily available.Purpose Prostate specific membrane antigen (PSMA) -ligand PET/CT is performed in patients with prostate cancer to stage the disease initially or to identify sites of recurrence after definitive therapy. 18F-PSMA-1007 is a promising PSMA-PET tracer based on clinical results, but detailed histologic confirmation has been lacking. Experimental Design 96 patients with prostate cancer received a 18F-PSMA-1007-PET/CT followed by either radical prostatectomy with lymphadenectomy or salvage lymphadenectomy. The histol